Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


03 enero 2018

Promising results for RenalGuard in heart failure patients

Cardiovascular News

According to a press release, a first-in-man feasibility study focusing on a novel use of the RenalGuard system to manage fluids during diuretic therapy in congestive heart failure patients suffering from fluid overload has shown positive results for the system. A previous meta-analysis found that the system reduces all-cause mortality in patients undergoing cardiac interventions.

13 diciembre 2017

Janssen seeks approval for rivaroxaban to be used to reduce cardiac events

Cardiovascular News

Janssen has submitted a supplemental new drug application to the US FDA for two new indications for rivaroxaban (Xarelto, which is marketed by Bayer in Europe): reducing the risk of major cardiovascular events such as cardiac death, myocardial infarction or stroke in patients with coronary artery disease and/or peripheral arterial disease; and for reducing the risk of acute limb ischaemia in patients with peripheral arterial disease.

11 diciembre 2017

Apple and Stanford Medicine launch app-based arrhythmia study

Cardiovascular News

Apple has launched the Apple Heart Study app, a first-of-its-kind research study using Apple Watch’s heart rate sensor to collect data on irregular heart rhythms and notify users who may be experiencing atrial fibrillation (AF).

11 diciembre 2017

Philips acquires cloud-based population health management solution provider VitalHealth

Cardiovascular News

Philips has acquired VitalHealth, a provider of cloud-based population health management solutions for the delivery of personalised care outside of the hospital. Headquartered in the Netherlands, a press release reports, VitalHealth’s products and services are being used by more than 100 healthcare networks in various countries including the USA, India, China, and the Netherlands.

06 diciembre 2017

Pollution may derail benefits of walking in older adults

Cardiovascular News

Fan Chung (National Heart & Lung Institute, Imperial College London, UK) and colleagues report in The Lancet that even short-term (two-hour) exposure to tiny particles of soot or dust found in traffic fumes on busy roads appears to thwart the benefits of walking on the heart and lungs among older adults (aged 60 or over). They report that short-term exposure to pollution is associated with stiffening of the arteries and impaired lung function, and strengthens the case to reduce vehicle emissions so that everyone can enjoy the health benefits of physical activity.

06 diciembre 2017

Global survey indicates that patients with type 2 diabetes underestimate their risk of cardiovascular disease

Cardiovascular News

According to the interim results of the first-ever multi-country online survey on cardiovascular disease risk awareness and knowledge among people living with type 2 diabetes, one in three respondents (943 overall) living with the condition consider their risk of cardiovascular disease to be low. Furthermore, the results indicate that one in six respondents had never discussed type 2 diabetes and cardiovascular risk with a healthcare professional.

05 diciembre 2017

STEMI patients at highest risk are less likely to receive optimal medical therapy

Cardiovascular News

Data from the regional emergency cardiovascular (RESCUe) network indicate that patients who have had a ST-segment elevation myocardial infarction (STEMI) and who are increased risk of future events are more likely to be under-treated with preventive pharmacological therapy than STEMI patients with fewer risk factors. They also show that, unsurprisingly, optimal medical therapy is associated with increased one-year survival.

05 diciembre 2017

EpicHeart soft-robotic heart assist device wins innovation award

Cardiovascular News

CorInnova has been awarded second prize in the “2017 InnoSTARS” life science competition for its EpicHeart soft-robotic heart assist device. The on-blood-contacting device is designed to be delivered minimally invasively to support heart function.

05 diciembre 2017

TCT 2017: FAME 2 provides support for PCI in stable disease after ORBITA

Cardiovascular News

Following ORBITA, which indicated percutaneous coronary intervention (PCI) did not provide benefit over a sham procedure in patients with stable coronary artery disease, the three-year results of the FAME-2 trial indicate that fractional flow reserve (FFR)-guided PCI improves clinical outcomes compared with medical management alone.

01 diciembre 2017

TCT 2017: Advances in device technology needed to improve outcomes with Absorb

Cardiovascular News

Data from the ABSORB IV study indicate that device thrombosis with the bioresorbable vascular scaffold (Absorb, Abbott) is substantially reduced when the device is not implanted into very small vessels. However, the study also showed greater ischaemia-driven target lesion failure with the scaffold than with a permanent metallic everolimus-eluting stent (Xience, Abbott)—indicating that device as well as technique improvements is necessary

01 diciembre 2017

Report calls for US to prioritise health resources towards diagnosing and diseases like cardiovascular disease

Cardiovascular News

A report—modified from US global health recommendations from the National Academies of Sciences, Engineering and Medicine (previously the Institute of Medicine) and published in Journal of the American College of Cardiology—states that the USA must prioritise its health resources toward detecting and treating non-communicable diseases such as cardiovascular disease.

30 noviembre 2017

Elunir drug-eluting stent approved for use in the USA

Cardiovascular News

Cordis and Medinol have announced that the US FDA has approval the Elunir drug-eluting stent for the treatment of patients with coronary artery disease. The stent, a press release reports, is designed with a novel metallic spring tip; it has the narrowest strut width of any stent on the US market.

29 noviembre 2017

China’s first human implantation of a retrievable TAVI device successfully completed

Cardiovascular News

The first human implantation of the VenusA Plus retrievable valve system was completed successfully at the Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU) on 23 November. Wang Jian’an (president of SAHZU) announced that China has completed its first successful human implantation of a retrievable transcatheter aortic valve implantation (TAVI) device.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.